Factors affecting readmission for acute asthmatic attacks in children | |
Abstract
readmission was a history of influenza vaccination (OR 0.24; 95% CI 0.16-0.36).
Factors affecting readmission for acute asthmatic attacks in children | |
Published: 10 April 2013
The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production. |
Incidence, clinical features and management of acute allergic reactions: the experience of a single, Italian Emergency Department
Published: 13 July 2013
The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production. |
Research
Published: 28 June 2013
The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production. |
| Received: | 28 February 2013 |
|---|---|
| Accepted: | 12 April 2013 |
| Published: | 28 June 2013 |
Javier de Miguel DÃez,1 Jorge Chancafe Morgan,1 Rodrigo Jiménez GarcÃa2
1Pulmonology Department, Gregorio Maranon University Hospital, Complutense University of Madrid, Madrid, Spain;Â 2Preventive Medicine and Public Health Teaching and Research Unit, Department of Health Sciences, Rey Juan Carlos University, Madrid, Spain
Abstract:Â Chronic obstructive pulmonary disease (COPD) is commonly associated with heart failure (HF) in clinical practice since they share the same pathogenic mechanism. Both conditions incur significant morbidity and mortality. Therefore, the prognosis of COPD and HF combined is poorer than for either disease alone. Nevertheless, usually only one of them is diagnosed. An active search for each condition using clinical examination and additional tests including plasma natriuretic peptides, lung function testing, and echocardiography should be obtained. The combination of COPD and HF presents many therapeutic challenges. The beneficial effects of selective Ã1-blockers should not be denied in stable patients who have HF and coexisting COPD. Additionally, statins, angiotensin-converting enzyme inhibitors, and angiotensin-receptor blockers may reduce the morbidity and mortality of COPD patients. Moreover, caution is advised with use of inhaled Ã2-agonists for the treatment of COPD in patients with HF. Finally, noninvasive ventilation, added to conventional therapy, improves the outcome of patients with acute respiratory failure due to hypercapnic exacerbation of COPD or HF in situations of acute pulmonary edema. The establishment of a combined and integrated approach to managing these comorbidities would seem an appropriate strategy. Additional studies providing new data on the pathogenesis and management of patients with COPD and HF are needed, with the purpose of trying to improve quality of life as well as survival of these patients.
Keywords:Â chronic obstructive pulmonary disease, heart failure
Post to:
CannoteaCiteulikeDel.icio.usFacebookLinkedInTwitter
 |Â
 |Â
 |Â
Research
| Received: | 11 February 2013 |
| Accepted: | 17 June 2013 |
| Published: | 19 June 2013 |
Chronic obstructive pulmonary disease; Obstructive sleep apnoea; Walking capacity; Autonomic dysfunction; Continuous positive airway pressure Keywords:Â
| Received: | 05 January 2013 |
|---|---|
| Accepted: | 22 March 2013 |
| Published: | 27 June 2013 |
Barbara P Yawn,1Â Yunfeng Li,2Â Haijun Tian,2Â Jie Zhang,2Â Steve Arcona,2Â Kristijan H Kahler2
1Department of Research, Olmsted Medical Center, Rochester, MN, USA;Â 2Department of Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
Background:Â The use of inhaled corticosteroids in patients with chronic obstructive pulmonary disease (COPD) has been associated with an increased risk of pneumonia in controlled clinical trials and case-control analyses.
Objective:Â Using claims databases as a research model of real-world diagnosis and treatment, to determine if the use and dose of inhaled corticosteroids (ICS) among patients with newly diagnosed COPD are associated with increased risk of pneumonia.
Patients and methods: This was a retrospective cohort analysis of patients diagnosed with COPD between January 01, 2006 and September 30, 2010, drawn from databases (years 2006â2010). Patients (aged â¥45 years) were followed until first pneumonia diagnosis, end of benefit enrollment, or December 31, 2010, whichever was earliest. A Cox proportional hazard model was used to assess the association of ICS use and risk of pneumonia, controlling for baseline characteristics. Daily ICS use was classified into low, medium, and high doses (1 µgâ499 µg, 500 µgâ999 µg, and â¥1000 µg fluticasone equivalents daily) and was modeled as a time-dependent variable.
Results:Â Among 135,445 qualifying patients with a total of 243,097 person-years, there were 1020 pneumonia incidences out of 5677 person-years on ICS (crude incidence rate, 0.180 per person-year), and 27,730 pneumonia incidences out of 237,420 person-years not on ICS (crude incidence rate, 0.117 per person-year). ICS use was associated with a dose-related increase in risk of pneumonia, with adjusted hazard ratios (versus no use; (95% confidence interval) of 1.38 (1.27â1.49) for low-dose users, 1.69 (1.52â1.88) for medium-dose users, and 2.57 (1.98â3.33) for high-dose users (PÂ -Â 0.01 versus no use and between doses).
Conclusion:Â The use of ICS in newly diagnosed patients with COPD is potentially associated with a dose-related increase in the risk of pneumonia.
Keywords:Â COPD, ICS, LABA, pneumonia
Post to:
CannoteaCiteulikeDel.icio.usFacebookLinkedInTwitter